Gonul Yardimci

Gonul Yardimci

Auto-generated profile, based on publicly available information

Gonul Yardimci

GULHANE TRAINING AND RESEARCH HOSPITAL

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2023 in Turkish Journal of Pediatric Disease
Verified
Journal Article
Open access
PDF file
SGSeçil Çakır Gündoğan
Seçil Çakır Gündoğan
AUAylin Kılınç Uğurlu
Aylin Kılınç Uğurlu
FGFatih Gürbüz
Fatih Gürbüz
GBGönül Büyükyılmaz
Gönül Büyükyılmaz
ABAbdurrahman Bi̇tkay
Abdurrahman Bi̇tkay
Emregül IşıkEmregül Işık
Emregül Işık
Objective: Publications have shown increased rate of precocious puberty and rapidly progressing puberty during the pandemic period. During the pandemic period, obesity has become widespread in children due to sedentary life, an increase in the time spent at home, and prolonged use of mobile devices. Obesity is a significant contributor to early puberty in females.We aimed to investigate whether obesity is a factor in the increase of puberty precocious cases during the pandemic. Material and Methods: In the study, female patients diagnosed with Puberty precocious /Rapidly Progressive Puberty in our clinic were divided into three groups August 2019-February 2020 before the pandemic (Group1-G1), August 2020-February 2021 during the pandemic (online education - Group2-G2), August 2021-February 2022 during the pandemic (face-to-face education -Group3-G3). The groups were retrospectively compared in terms of clinical, laboratory, and imaging findings. Results: A total of 495 female patients were included in the study. There was no difference between the groups in terms of age at the presentation. The most common complaint at presentation in the three groups was thelarche. Also, presentation with combination of thelarche and pubarche was more common in G3, and presentation due to menarche was more common in G2 (p=0.011). No difference was found between the groups regarding body weight SDS, and height SDS. The BMI SDS was 0.69±1 SD for all patients, 0.78±0.94 SD for G1, 0.67±1 SD for G2, and 0.67±1 for G3, and the BMI SDS of the groups were comparable (p=0.630). The majority of patients at the presentation were Breast Tanner stage 3. G2 (9%) and G3 (9%) were presented with Breast Tanner stage 4 at a higher frequency compared to G1 (2%). There was no difference between the groups’ FSH, LH, estradiol, LHRH test peak FSH, peak LH, and LH/FSH values. There was no difference between the bone ages of the groups at the presentation. The uterus size, right and left ovary volumes of G2 and G3 were significantly bigger than those of G1 (p=0.001). No difference was found between the groups in the rates of precocious puberty and rapidly progressing puberty cases. Conclusion: In our study, the age at presentation and BMI were similar pre-pandemic group G1 and during the pandemic, online education (G2) and pandemic face-to-face education (G3). We determined that obesity may not be one of the factors triggering precocious puberty cases during the pandemic period.

19 August 2025 in Calcified Tissue International
Verified
Journal Article
Closed access
PDF file
GBGonul Buyukyilmaz
Gonul Buyukyilmaz
SKSerkan Bilge Koca
Serkan Bilge Koca
RGRefika Gören
Refika Gören
EUEsma Andaç Uzdogan
Esma Andaç Uzdogan
KAKeziban Toksoy Adıguzel
Keziban Toksoy Adıguzel
FGFatih Gürbüz
Fatih Gürbüz

11 October 2025 in Calcified Tissue International
Verified
Journal Article
Open access
PDF file
GBGonul Buyukyilmaz
Gonul Buyukyilmaz
SKSerkan Bilge Koca
Serkan Bilge Koca
RGRefika Gören
Refika Gören
EUEsma Andaç Uzdogan
Esma Andaç Uzdogan
KAKeziban Toksoy Adıguzel
Keziban Toksoy Adıguzel
FGFatih Gürbüz
Fatih Gürbüz

23 January 2026 in Sağlık Bilimlerinde Değer
Verified
Journal Article
Closed access
BTBanu Turhan
Banu Turhan
GBGönül Büyükyılmaz
Gönül Büyükyılmaz
KAKeziban Toksoy Adıgüzel
Keziban Toksoy Adıgüzel
EÖEmre Özer
Emre Özer
GYGönül Yardımcı
Gönül Yardımcı
MBMehmet Boyraz
Mehmet Boyraz
Aim: Pamidronate is the preferred treatment for osteoporosis and hypercalcemia in children. This study examined its safety and effectiveness. Material and Methods: Patients treated with pamidronate for osteoporosis and hypercalcemia were included in the study. Osteoporosis patients received 1 mg/kg/day every three months for three days, while hypercalcemia patients received a single 1 mg/kg dose. Evaluations of height, weight, body mass index, bone mineral density (BMD), fractures, biochemical data, and complications were performed before and at least six months after treatment. Results: Of the 31 patients included in the study, 21 (67.7%) were male and 10 (32.3%) were female, with a mean age of 12.20 ±4.31 years. Secondary osteoporosis was diagnosed in 20 (64.5%) patients, primary osteoporosis associated with osteogenesis imperfecta in seven (22.6%) patients, and hypercalcemia in four (12.9%) patients. The average follow-up period was 11.26 ±4.16 months. The mean BMD before treatment in patients treated with pamidronate for osteoporosis was -3.53 ±1.43, while after treatment it was -1.42 ±1.81 (p<0.001). When comparing the pre- and post-treatment periods, a decrease was observed in the total number of fractures, the number of vertebral fractures, and the number of fractures occurring more than once per year (p<0.001). Complications were observed in six (19,3%) patients but all these side effects were temporary. Conclusion: Pamidronate treatment was administered at varying doses and for differing durations to patients from multiple groups, with no significant differences in efficacy or safety observed. The low complication rates reported are consistent with the literature and substantiate the safety of the treatment.